Intellect Neurosciences Inc (ILNS) 0.0220 $ILNS
Intellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program
Marketwired - Wed Mar 30, 9:29AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS), a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative orphan diseases with no approved therapies, announced today that it has appointed Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor. Dr. Freilich has agreed to assist the company in shaping and guiding the company's CONJUMAB-A antibody drug conjugate (ADC) program, and in particular, to advise the company on the design of CONJUMAB-A and future pre-clinical and clinical studies targeting Age-Related Macular Degeneration (AMD).
New Peer Reviewed Article Describes Role of TauC3 in AD Transgenic Mice
Marketwired - Thu Jan 07, 7:36AM CST
Intellect Neurosciences, Inc. (OTCQB: ILNS) ("Company" or "Intellect"
, a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, today announced the publication of a scientific study of the role of TauC3 in transgenic mice in the prominent, peer-reviewed journal, Neurobiology of Disease [2015, 87:19-28]. The paper, titled "Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model," describes the findings of a recent preclinical study of caspase-cleaved tau in a transgenic mouse model. The study marks the first published study indicating that the expression of caspase-cleaved tau (TauC3) in mice induces early memory deficit and reduced synaptic density. In addition, the study demonstrated that hyperphosphorylated tau oligomers and aggregates appear in TauC3 mice showing memory deficit and that aggregation blocker or rapamycin rescues memory impairment and reduces tau oligomers in TauC3 mice. The TauC3 mouse in the study is an Alzheimer's disease (AD) model used elucidate tau oligomer-associated pathogenesis and to evaluate therapeutic drug options. The paper was co-authored by scientists at the Global Research Laboratory, School of Biological Sciences, Seoul National University, Seoul, and the Department of Neurology and Neuroscience & Cell Biology, University of Texas, Galveston, Texas.
Intellect Neurosciences, Inc. Engages Troy Rohn, PhD as Lead Scientific Advisor for TauC3 Antibody Program
Marketwired - Mon Oct 26, 7:02AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, announced today that it has appointed Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, Boise, Idaho, as lead scientific advisor. Dr. Rohn has agreed to assist the company in shaping and guiding the company's TauC3 antibody program, and in particular, to identify one or more orphan diseases in which TauC3 is an appropriate target and for which the company's TauC3 antibody may be an effective therapeutic agent.
Intellect Neurosciences, Inc. Issues Letter to Shareholders
Marketwired - Tue Oct 20, 7:25AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, issued the following Letter to Shareholders from Elliot Maza, CEO.
Intellect Neurosciences Common Stock Approved for Trading on OTCQB
Marketwired - Wed Apr 15, 7:02AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced that its securities have been designated as trading on the OTCQB marketplace. Intellect has satisfactorily passed the requirements for eligibility, which include up to date reporting to the SEC, a minimum bid price test of one penny and an annual verification and management certification process providing additional information about the company's insiders, advisors and share count. As a result of the designation, among other things, Intellect investors will enjoy greater information availability through news and disclosure posted through the OTC Disclosure & News Service and transparent prices through full-depth of book with Real Time Level 2 quotes.
Intellect Neurosciences, Inc. Engages Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor for CONJUMAB-A Antibody Drug Conjugate Program
Marketwired - Wed Mar 30, 9:29AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS), a research-based biotechnology company focused on the discovery, development and licensing of novel disease-modifying therapeutics for the treatment and prevention of rare neurodegenerative orphan diseases with no approved therapies, announced today that it has appointed Benjamin D. Freilich, MD, FACS as Senior Medical Affairs Advisor. Dr. Freilich has agreed to assist the company in shaping and guiding the company's CONJUMAB-A antibody drug conjugate (ADC) program, and in particular, to advise the company on the design of CONJUMAB-A and future pre-clinical and clinical studies targeting Age-Related Macular Degeneration (AMD).
New Peer Reviewed Article Describes Role of TauC3 in AD Transgenic Mice
Marketwired - Thu Jan 07, 7:36AM CST
Intellect Neurosciences, Inc. (OTCQB: ILNS) ("Company" or "Intellect"
, a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, today announced the publication of a scientific study of the role of TauC3 in transgenic mice in the prominent, peer-reviewed journal, Neurobiology of Disease [2015, 87:19-28]. The paper, titled "Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model," describes the findings of a recent preclinical study of caspase-cleaved tau in a transgenic mouse model. The study marks the first published study indicating that the expression of caspase-cleaved tau (TauC3) in mice induces early memory deficit and reduced synaptic density. In addition, the study demonstrated that hyperphosphorylated tau oligomers and aggregates appear in TauC3 mice showing memory deficit and that aggregation blocker or rapamycin rescues memory impairment and reduces tau oligomers in TauC3 mice. The TauC3 mouse in the study is an Alzheimer's disease (AD) model used elucidate tau oligomer-associated pathogenesis and to evaluate therapeutic drug options. The paper was co-authored by scientists at the Global Research Laboratory, School of Biological Sciences, Seoul National University, Seoul, and the Department of Neurology and Neuroscience & Cell Biology, University of Texas, Galveston, Texas. Intellect Neurosciences, Inc. Engages Troy Rohn, PhD as Lead Scientific Advisor for TauC3 Antibody Program
Marketwired - Mon Oct 26, 7:02AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, announced today that it has appointed Dr. Troy Rohn, Professor, Department of Biological Sciences, Boise State University, Boise, Idaho, as lead scientific advisor. Dr. Rohn has agreed to assist the company in shaping and guiding the company's TauC3 antibody program, and in particular, to identify one or more orphan diseases in which TauC3 is an appropriate target and for which the company's TauC3 antibody may be an effective therapeutic agent.
Intellect Neurosciences, Inc. Issues Letter to Shareholders
Marketwired - Tue Oct 20, 7:25AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of rare neurodegenerative conditions, issued the following Letter to Shareholders from Elliot Maza, CEO.
Intellect Neurosciences Common Stock Approved for Trading on OTCQB
Marketwired - Wed Apr 15, 7:02AM CDT
Intellect Neurosciences, Inc. (OTCQB: ILNS) a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic and diagnostic agents for the treatment of Alzheimer's and other neurological diseases, today announced that its securities have been designated as trading on the OTCQB marketplace. Intellect has satisfactorily passed the requirements for eligibility, which include up to date reporting to the SEC, a minimum bid price test of one penny and an annual verification and management certification process providing additional information about the company's insiders, advisors and share count. As a result of the designation, among other things, Intellect investors will enjoy greater information availability through news and disclosure posted through the OTC Disclosure & News Service and transparent prices through full-depth of book with Real Time Level 2 quotes.
